FB-101 vs Risvodetinib (IkT-148009)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: c-Abl · full Parkinson's Disease pipeline

FB-101

Developed by 1ST Biotherapeutics, Inc.

Phase 1 in Parkinson's Diseasesmall molecule
Weak signal

NCT04165837 · Phase 1 · completed

Participants were randomized to FB-101 or placebo with blinding of participants, care providers, and investigators, but the primary endpoint is adverse-event incidence in healthy volunteers rather than a Parkinson's disease outcome, and no results have been posted. Its registered primary outcome on ClinicalTrials.gov is "Number and severity of treatment emergent adverse events (TEAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Risvodetinib (IkT-148009)

Developed by ABLi Therapeutics, Inc. under a licence from Inhibikase Therapeutics

Phase 2 in Parkinson's Diseasesmall molecule
Weak signal

NCT05424276 · Phase 2 · completed

The trial was well designed - randomized, blinded, and placebo-controlled with roughly 33-35 patients per arm - but its designated primary endpoint was adverse-event incidence rather than a disease-related clinical outcome, and no statistical comparison across arms was reported for that primary endpoint (event rates were similar across all four groups: 54-64%). The efficacy-related measures (MDS-UPDRS, PDQ-39, etc.) were only secondary and the study was explicitly stated as not powered to detect efficacy differences, with results showing no consistent separation from placebo. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment-emergent Adverse Events (TEAEs)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Incidence of Treatment-emergent Adverse Events (TEAEs) (Baseline to 12 weeks); Proportion of Those Randomized in Each Dosing Cohort Who Discontinued the Assigned Regimen Due to an Adverse Event (Baseline to 12 weeks): Incidence of Treatment-emergent Adverse Events (TEAEs) (Baseline to 12 weeks): 50mg IkT-148009 (Risvodetinib) 19 Participants | 100mg IkT-148009 (Risvodetinib) 21 Participants | 200mg IkT-148009 (Risvodetinib) 21 Participants | Placebo 21 Participants (unclear)

Result source: NCT05424276

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFB-101Risvodetinib (IkT-148009)
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported—Not reported
MDS-UPDRS Part II, change—Not reported-0.1 vs 1.1−1.2 vs placebo200 mg · wk 12 · n 29NCT05424276
2 other results
  • -0.3 vs 1.1 100 mg · wk 12 · n 32 · Phase 2 · secondary NCT05424276
  • 0.1 vs 1.1 50 mg · wk 12 · n 32 · Phase 2 · secondary NCT05424276

OFF time, change

FB-101
—Not reported
Risvodetinib (IkT-148009)
—Not reported

ON time without troublesome dyskinesia, change

FB-101
—Not reported
Risvodetinib (IkT-148009)
—Not reported

UPDRS Part III, change

FB-101
—Not reported
Risvodetinib (IkT-148009)
—Not reported

MDS-UPDRS Part II, change

FB-101
—Not reported
Risvodetinib (IkT-148009)
-0.1 vs 1.1−1.2 vs placebo200 mg · wk 12 · n 29NCT05424276
2 other results
  • -0.3 vs 1.1 100 mg · wk 12 · n 32 · Phase 2 · secondary NCT05424276
  • 0.1 vs 1.1 50 mg · wk 12 · n 32 · Phase 2 · secondary NCT05424276
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

FB-101: no structured comparison results are available for Parkinson's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. FB-101: 0 of 4 rows · Risvodetinib (IkT-148009): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRisvodetinib (IkT-148009)
Dropout rate
15.2%200 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
8.8%100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
11.4%50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
Discontinued due to AEs
0%200 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
0%100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
2.9%50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
Serious AEs
3%200 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
0%100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
2.9%50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
Most frequent reported AEs
200 mg
diarrhoea 12.1% (placebo 11.4%)
headache 9.1% (placebo 2.9%)
muscle spasms 9.1% (placebo 2.9%)
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
100 mg
constipation 8.8% (placebo 8.6%)
back pain 5.9% (placebo 0%)
fall 5.9% (placebo 14.3%)
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
50 mg
covid-19 11.4% (placebo 2.9%)
nasopharyngitis 8.6% (placebo 8.6%)
fatigue 5.7% (placebo 2.9%)
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Risvodetinib (IkT-148009)

MDS-UPDRS II III 2.12 vs 0.85 placebo score @ 12wk200 mg
absolute change · score
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
1.82 vs 0.85 placebo score @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
0.08 vs 0.85 placebo score @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
PDQ-39 -1.89 vs -2.35 placebo score @ 12wk200 mg
absolute change · score
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
-0.99 vs -2.35 placebo score @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
-1.9 vs -2.35 placebo score @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
PGI-S 0.03 vs -0.04 placebo score @ 12wk200 mg
absolute change · score
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
0.13 vs -0.04 placebo score @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
0.04 vs -0.04 placebo score @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
CGI-S -0.02 vs 0.11 placebo score @ 12wk200 mg
absolute change · score
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
0.13 vs 0.11 placebo score @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
-0.08 vs 0.11 placebo score @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
MDS-UPDRS Part II -0.08 vs 1.09 placebo score @ 12wk200 mg
absolute change · score
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
-0.32 vs 1.09 placebo score @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
0.11 vs 1.09 placebo score @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
MDS-UPDRS Part III 2.2 vs -0.21 placebo score @ 12wk200 mg
absolute change · score
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
2.14 vs -0.21 placebo score @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
-0.04 vs -0.21 placebo score @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
MDS-UPDRS Part I 0.22 vs -0.26 placebo score @ 12wk200 mg
absolute change · score
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
-1.03 vs -0.26 placebo score @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
-0.93 vs -0.26 placebo score @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
NMSS 0.88 vs -0.14 placebo score @ 12wk200 mg
absolute change · score
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
0.79 vs -0.14 placebo score @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
0.14 vs -0.14 placebo score @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
CSBM -0.11 vs 0.85 placebo per week @ 12wk200 mg
absolute change · per week
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
0.3 vs 0.85 placebo per week @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
-0.04 vs 0.85 placebo per week @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
ESS -0.76 vs -0.68 placebo score @ 12wk200 mg
absolute change · score
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
-0.3 vs -0.68 placebo score @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
-0.46 vs -0.68 placebo score @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
SE-ADL 0 vs -0.02 placebo score @ 12wk200 mg
absolute change · score
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
0 vs -0.02 placebo score @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
0.02 vs -0.02 placebo score @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
PAGI-SYM -0.09 vs 0.05 placebo score @ 12wk200 mg
absolute change · score
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
show 2 more results
-0.02 vs 0.05 placebo score @ 12wk100 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2
-0.04 vs 0.05 placebo score @ 12wk50 mg
NCT05424276 · Phase 2 · monotherapy · Parkinson's Disease · phase 2

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: FB-101's landscape · Risvodetinib (IkT-148009)'s landscape